With accelerating development of personalized cancer treatments matched to a patient’s DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualized therapy.
In a paper published in the May 5 online issue of The Oncologist, researchers at the University of California, San Diego School of Medicine and Moores Cancer Center detail their experience evaluating 34 patients between December 2012 and June 2013 using a molecular tumor board – a new type of advisory group comprised of multidisciplinary experts, including those in the fields of tumor genetics, basic science and bioinformatics. … Read the full story from the UC San Diego Newsroom
